Видео ютуба по тегу Michael Mauro

ASCEMBL: asciminib versus bosutinib in third-line treatment of CP-CML
ASCEMBL: asciminib versus bosutinib in third-line treatment of CP-CML
ASH Meeting on Hematologic Malignancies: Michael Mauro, MD
ASH Meeting on Hematologic Malignancies: Michael Mauro, MD
Ponatinib Efficacy and Safety With the T315I Mutation: Long-Term Follow-up of Phase 1&2 Trials
Ponatinib Efficacy and Safety With the T315I Mutation: Long-Term Follow-up of Phase 1&2 Trials
Drs. Kantarjian and Mauro discuss ELVN-001 in CML
Drs. Kantarjian and Mauro discuss ELVN-001 in CML
Dr. Michael Mauro DO, Orthopedic Spine Surgeon at Healthpointe
Dr. Michael Mauro DO, Orthopedic Spine Surgeon at Healthpointe
New drugs for CML: are more to come?
New drugs for CML: are more to come?
Considerations for Patients Taking Ponatinib - Michael Mauro, MD, NCMLS Medical Advisor
Considerations for Patients Taking Ponatinib - Michael Mauro, MD, NCMLS Medical Advisor
Dr. Michael Mauro on Toxicities of TKI Usage in CML Patients
Dr. Michael Mauro on Toxicities of TKI Usage in CML Patients
Unmet needs in pediatric CML
Unmet needs in pediatric CML
Dr. Michael Mauro on Treatment Discontinuation for CML
Dr. Michael Mauro on Treatment Discontinuation for CML
A Word from Michael Mauro, MD - Team 922
A Word from Michael Mauro, MD - Team 922
Michael Mauro Discusses Therapy-Free CML Remission
Michael Mauro Discusses Therapy-Free CML Remission
Managing cardiovascular risks associated with lifelong TKI therapy in CML
Managing cardiovascular risks associated with lifelong TKI therapy in CML
What's In Michael Mauro's Wildlife Cinematography Camera Pack
What's In Michael Mauro's Wildlife Cinematography Camera Pack
Sinatra The Way You Look Tonight Cover by Michael Mauro
Sinatra The Way You Look Tonight Cover by Michael Mauro
When to Switch Therapy in Chronic Myeloid Leukemia
When to Switch Therapy in Chronic Myeloid Leukemia
Asciminib found to be safe and effective for heavily pretreated patients with chronic myeloid le...
Asciminib found to be safe and effective for heavily pretreated patients with chronic myeloid le...
Fourth generation TKIs for CML: asciminib
Fourth generation TKIs for CML: asciminib
Dr. Mauro Discusses Drug Adherence Among CML Patients
Dr. Mauro Discusses Drug Adherence Among CML Patients
Bosutinib: a new, safer TKI for frontline CML
Bosutinib: a new, safer TKI for frontline CML
Asciminib has the potential to succeed where other TKIs have failed in CML
Asciminib has the potential to succeed where other TKIs have failed in CML
NCMLS_Ash Dr. Mauro
NCMLS_Ash Dr. Mauro
Michael Mauro - Talk To Me 1983 Complete 12'' Maxi
Michael Mauro - Talk To Me 1983 Complete 12'' Maxi
MICHAEL MAURO - Talk To Me (7'' Version) - 1983
MICHAEL MAURO - Talk To Me (7'' Version) - 1983
The Michael Mauro Show Intro
The Michael Mauro Show Intro